Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE

被引：1

作者：

Piroth, Lionel ^{[1
,2
]}

Vitrat, Virginie ^{[3
]}

Le Moing, Vincent ^{[4
]}

Bret, Philippe ^{[5
]}

Brault, Yves ^{[5
]}

Greenwood, William ^{[5
]}

Chopin, Marie-Charlotte ^{[6
]}

Vicaut, Eric ^{[7
,8
]}

Montravers, Philippe ^{[9
,10
]}

Tattevin, Pierre ^{[11
]}

Bleibtreu, Alexandre ^{[12
,13
]}

OZAVIE Res Grp

机构：

[1] Univ Burgundy, Dijon Bourgogne Univ Hosp, Dept Infect Dis, Dijon, France

[2] Univ Burgundy, INSERM, CIC1432, Dijon, France

[3] Annecy Genevois Hosp, Dept Infect Dis & Internal Med, Annecy, France

[4] Montpellier Univ Hosp, Dept Infect Dis, Montpellier, France

[5] Pfizer, Paris, France

[6] Lille Univ Hosp, Dept Infect Dis, Lille, France

[7] St Louis Lariboisiere Fernand Widal Hosp, Clin Res Unit, Paris, France

[8] Paris Cite Univ, Paris, France

[9] APHP, Bichat Claude Bernard Hosp, Anaesthesiol & Surg Intens Care Unit, Paris, France

[10] Univ Paris Cite, Paris, France

[11] Pontchaillou Univ Hosp, Infect Dis & Intens Care Unit, Rennes, France

[12] APHP, Pitie Salpetrie Hosp, Dept Infect Dis, Paris, France

[13] Sorbonne Univ, Paris, France

来源：

INFECTIOUS DISEASES NOW | 2025年 / 55卷 / 02期

关键词：

Ceftazidime-avibactam; Multidrug-resistant bacteria; Gram-negative bacteria; Prospective study; Effectiveness; RESISTANCE; EMERGENCE; OUTCOMES;

D O I：

10.1016/j.idnow.2025.105036

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: While difficult-to-treat multidrug-resistant Gram-negative bacteria infections increase over time, the real-world effectiveness, use, and safety of ceftazidime-avibactam (CAZ-AVI) for treating hospitalized patients was assessed in 41 French centers. Procedures: OZAVIE was a prospective, multicenter, observational study conducted between March 2019 and November 2021. Hospitalized adult patients having initiated CAZ-AVI for infections within 14 days before enrolment were eligible. Demographic, clinical, microbiological, and therapeutic data were collected. Outcome was categorized as "failure" if the patient died from the initial infection, or if the infections persisted and required another antibiotic or surgery, or if CAZ-AVI was discontinued due to intolerance, and as "global success" otherwise. Patients whose outcome was not "failure", did not die and required no other antibiotics during the index hospitalization were categorized as "therapeutic success". Results: 257 patients were enrolled: 76 females/181 males, mean age 58.4 years, with diabetes (30.0 %), chronic renal failure (25.7 %), end-stage liver disease (9.3 %) and/or immunocompromised (31.1 %). CAZ-AVI was prescribed for nosocomial pneumonia (34.2 %), complicated urinary tract infections (17.5 %), complicated intraabdominal infections (14.8 %) and other specified sites (27.6 %). The main pathogens were Pseudomonas aeruginosa (52.4 %), Klebsiella spp. (34.9 %), Enterobacter spp. (18.4 %). Global and therapeutic successes were observed in 79.0 % and 63.4 % of patients, respectively, and 28-day mortality was 20.2 %. Overall, adverse events possibly related to CAZ-AVI were reported in 17.4 % of patients, including serious AEs in 6.2 %. Conclusions: CAZ-AVI is effective and well tolerated for treating various infections - including difficult-to-treat infection sites - and for treating various infections strains, including Pseudomonas aeruginosa and Enterobacter spp.

引用

页数：8

共 28 条

[1] Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients [J].